{"id":3794,"date":"2000-08-16T15:53:27","date_gmt":"2000-08-16T14:53:27","guid":{"rendered":"http:\/\/moomango.co.uk\/htb\/?p=3794"},"modified":"2013-09-30T07:29:00","modified_gmt":"2013-09-30T07:29:00","slug":"prednisone-and-nevirapine-rash","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/3794","title":{"rendered":"Prednisone and nevirapine rash"},"content":{"rendered":"<p><strong>Simon Collins, HIV i-Base<\/strong><\/p>\n<p><strong>Results of an uncontrolled study presented at ICAAC in 1998 found that using prednisone (40-50mg QD) during the first two weeks of nevirapine therapy led to a reduced incidence of rash (in 1\/83 against 10\/72 without prednisone). <\/strong><\/p>\n<p>This led many clinicians to prescribe short courses of prednisone for patients starting nevirapine-based combinations.<\/p>\n<p>In Durban, a Canadian study from Julio Montaner group found opposite results. This controlled open-label study in 138 patients (66 of whom were treatment naive) randomised half of the group to receive prednisone (40mg QD) and half to receive nothing.<\/p>\n<p>Analysis was performed after all patients had completed six weeks treatment &#8211; the risk period for NVP-associated rash. The incidence of rash was higher in the prednisone group (36% against 18%) most of which were mild to moderate severity. The majority of rashes were mild (55%) or moderate (9%). Serious rash only occurred in the prednisone group (9% vs 0%).<\/p>\n<p><strong>Table 1<\/strong><\/p>\n<table border=\"0\">\n<tbody>\n<tr>\n<td><\/td>\n<td><strong> Prednisone <\/strong><\/td>\n<td><strong>No prednisone<\/strong><\/td>\n<td><\/td>\n<\/tr>\n<tr>\n<td><strong>Rash <\/strong><\/td>\n<td>36% (25\/69)<\/td>\n<td>18% (13\/69)<\/td>\n<td>p = 0.022<\/td>\n<\/tr>\n<tr>\n<td><strong>Serious rash<\/strong><\/td>\n<td>9% (6\/69)<\/td>\n<td>0%<\/td>\n<td><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Reference:<\/p>\n<ol>\n<li>Montaner J, Gigliotti M, Cahn P et al. The effects of a short course of prednisone (pred) on the incidence of rash associated with nevirapine (NVP, VIRAMUNE). XIII International AIDS Conference, Durban, July 9-14, 2000. Abstract WePpB1378.<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"<p>Simon Collins, HIV i-Base Results of an uncontrolled study presented at ICAAC in 1998 found that using prednisone (40-50mg QD) during the first two weeks of nevirapine therapy led to a reduced incidence of rash (in 1\/83 against 10\/72 without &hellip;<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4,8],"tags":[148],"class_list":["post-3794","post","type-post","status-publish","format-standard","hentry","category-conference-reports","category-side-effects","tag-aids-13th-durban-2000"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/3794","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=3794"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/3794\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=3794"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=3794"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=3794"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}